Inhibitors of AKT/PKB with anti-tumor activity
The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering all effective amount of a compound of formula I to the person or animal.
1. A method for inhibiting the Akt/PKB pathway in a cancer cell in which said pathway is present, wherein said cell constitutively expresses an Akt protein or said cell expresses elevated levels of an Akt protein, said method comprising contacting the cell with an effective amount of a compound according to formula (I):
wherein
X is N;
Y is O, NH, or S;
R 1 is, independently, —H, —OH, —NH 2 , —NO 2 , halogen, alkyl optionally substituted with —OH, or alkoxy optionally substituted with —OH;
R 2 is —C(O)NH 2 or alkoxy optionally substituted with —OH, halogen, alkyl, or alkoxy;
R 3 is —OH, —NH 2 , —C(O)NH 2 , or alkoxy optionally substituted with —OH, halogen, alkyl, or alkoxy; or
a pharmaceutically acceptable salt thereof;
or a composition comprising said compound.
2. The method according to claim 1 , wherein
the compound is administered intravenously or intranasaly; and the effective amount of the compound of formula (I) is 0.01 to about 20 mg/kg of body weight; or
the compound is administered intraperitonealy, subcutaneously, or intramuscularly; and the effective amount of the compound of formula (I) is 0.01 to about 100 mg/kg of body weight; or
the compound is administered orally; and the effective amount of the compound of formula (I) is 0.01 to about 200 mg/kg of body weight.
3. The method of claim 1 , wherein each X is N or Y is O.
4. The method of claim 1 , wherein each R 1 is independently —OH or —CH 2 OH.
5. The method of claim 1 , wherein R 2 is —C(O)NH 2 .
6. The method of claim 1 , wherein the compound is API-1.
7. The method of claim 1 , wherein the compound is according to formula (II):
or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the compound is according to the following formula:
or a pharmaceutically acceptable salt thereof.
9. A method for inhibiting the Akt/PKB pathway in a malignant tumor cell in which said pathway is present, wherein said cell constitutively expresses an Akt protein or said cell expresses elevated levels of an Akt protein, said method comprising contacting the cell with an effective amount of a compound according to formula (I):
wherein
X is N;
Y is O, NH, or S;
R 1 is, independently, —H, —OH, —NH 2 , —NO 2 , halogen, alkyl optionally substituted with —OH, or alkoxy optionally substituted with —OH;
R 2 is —C(O)NH 2 or alkoxy optionally substituted with —OH, halogen, alkyl, or alkoxy;
R 3 is —OH, —NH 2 , —C(O)NH 2 , or alkoxy optionally substituted with —OH, halogen, alkyl, or alkoxy; or
a pharmaceutically acceptable salt thereof;
or a composition comprising said compound.
10. The method according to claim 9 , wherein
the compound is administered intravenously or intranasaly; and the effective amount of the compound of formula (I) is 0.01 to about 20 mg/kg of body weight; or
the compound is administered intraperitonealy, subcutaneously, or intramuscularly; and the effective amount of the compound of formula (I) is 0.01 to about 100 mg/kg of body weight; or
the compound is administered orally; and the effective amount of the compound of formula (I) is 0.01 to about 200 mg/kg of body weight.
11. The method of claim 9 , wherein each X is N or Y is O.
12. The method of claim 9 , wherein each R 1 is independently —OH or —CH 2 OH.
13. The method of claim 9 , wherein R 2 is —C(O)NH 2 .
14. The method of claim 9 , wherein the compound is API-1.
15. The method of claim 9 , wherein the compound is according to formula (II):
or a pharmaceutically acceptable salt thereof.
16. The method of claim 9 , wherein the compound is according to the following formula:
or a pharmaceutically acceptable salt thereof.